Literature DB >> 14637017

Topology of factor VIII bound to phosphatidylserine-containing model membranes.

Vivek S Purohit1, Karthik Ramani, Ramesh S Kashi, Manzer J Durrani, Timothy J Kreiger, Sathyamangalam V Balasubramanian.   

Abstract

Factor VIII (FVIII), a plasma glycoprotein, is an essential cofactor in the blood coagulation cascade. It is a multidomain protein, known to bind to phosphatidylserine (PS)-containing membranes. Based on X-ray and electron crystallography data, binding of FVIII to PS-containing membranes has been proposed to occur only via the C2 domain. Based on these models, the molecular topology of membrane-bound FVIII can be envisioned as one in which only a small fraction of the protein interacts with the membrane, whereas the majority of the molecule is exposed to an aqueous milieu. We have investigated the topology of the membrane-bound FVIII using biophysical and biochemical techniques. Circular dichroism (CD) and fluorescence studies indicate no significant changes in the secondary and tertiary structure of FVIII associated with the membranes. Acrylamide quenching studies show that the protein is predominantly present on the surface of the membrane, exposed to the aqueous milieu. The light scattering and electron microscopy studies indicate the absence of vesicle aggregation and fusion. Binding studies with antibodies directed against specific epitopes in the A1, A2 and C2 domains suggest that FVIII binds to the membrane primarily via C2 domain including the specific phospholipid binding epitope (2303-2332) and may involve subtle conformational changes in this epitope region.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14637017     DOI: 10.1016/j.bbamem.2003.08.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model.

Authors:  Radha Ramakrishnan; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2016-07-16       Impact factor: 3.534

2.  Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.

Authors:  Puneet Gaitonde; Aaron Peng; Robert M Straubinger; Richard B Bankert; Sathy V Balu-Iyer
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

3.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

4.  Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model.

Authors:  Fiona Y Glassman; Sathy V Balu-Iyer
Journal:  Int J Pharm       Date:  2018-07-05       Impact factor: 5.875

5.  Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.

Authors:  Matthew P Kosloski; Aaron Peng; Prashant R Varma; Anas M Fathallah; Razvan D Miclea; Donald E Mager; Sathy V Balu-iyer
Journal:  Drug Deliv       Date:  2010-11-30       Impact factor: 6.419

6.  Phosphatidylinositol induces fluid phase formation and packing defects in phosphatidylcholine model membranes.

Authors:  Aaron Peng; Dipak S Pisal; Amy Doty; Sathy V Balu-Iyer
Journal:  Chem Phys Lipids       Date:  2011-10-17       Impact factor: 3.329

7.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

8.  Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.

Authors:  Karthik Ramani; Razvan D Miclea; Vivek S Purohit; Donald E Mager; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2008-04       Impact factor: 3.534

9.  O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.

Authors:  Razvan D Miclea; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

10.  Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.

Authors:  Karthik Ramani; Vivek Purohit; Razvan Miclea; Puneet Gaitonde; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.